Drug targeting strategies

P. S. Huang, A. Oliff, Drug-Targeting Strategies in Cancer Therapy , Curr. Opin. Genet. Dev. 2001, 11, 104-110. 

Of the non-antibody, non-liposome based drug targeting strategies, most of the (limited) clinical experience has been obtained with polymer-based conjugates of anticancer drugs. The most widely employed drugs for this application are cytotoxic agents such as doxorubicin and... 

Table 1.3. Overview of recently reported clinical studies with miscellaneous drug targeting strategies.

Similar to drug targeting strategies aimed at multiple target epitopes, a drug that intervenes at various stages of cell activation may be exploited for effective blockade of endothelial cell involvement in chronic inflammation. 

The studies presented above represent the most advanced pre-clinical and clinical therapy programmes for cancer management including drug targeting strategies. Patience is required... 

Of the target epitopes suggested for use in tumour vasculature directed drug targeting strategies (Table 9.1), those discussed above seem to be the most promising for development for clinical application. A few have not been extensively studied for this purpose but may also be interesting candidates, and are therefore discussed below. 

---